Aventis Arava

Rheumatoid arthritis disability prevention sNDA withdrawn Feb. 1. FDA plans to review standards for the indication, Aventis says. The Feb. 9 meeting of the FDA Arthritis Drugs Advisory Committee to discuss the new indication for leflunomide has been cancelled